Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals

BACKGROUND: In Italy, anti-HCV drugs are provided free of charge by the National Health System. Since 2011, three drug regimens including a directly acting antiviral (DAA) are considered the gold standard for HCV treatment. However, these drugs add a significant cost (roughly €26,000) to the combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Strazzulla, Alessio, Costa, Chiara, Pisani, Vincenzo, De Maria, Vincenzo, Giancotti, Francesca, Di Salvo, Sebastiano, Parisi, Saverio Giuseppe, Basso, Monica, Franzetti, Marzia Maria, Marascio, Nadia, Liberto, Maria Carla, Barreca, Giorgio Settimo, Lamberti, Angelo Giuseppe, Zicca, Emilia, Postorino, Maria Concetta, Matera, Giovanni, Focà, Alfredo, Torti, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160897/
https://www.ncbi.nlm.nih.gov/pubmed/25236374
http://dx.doi.org/10.1186/1471-2334-14-S5-S3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160897/
https://www.ncbi.nlm.nih.gov/pubmed/25236374
http://dx.doi.org/10.1186/1471-2334-14-S5-S3

Ejemplares similares